General principle on planning and design of Multi-Regional Clinical Trials
|
|
- Steven Newton
- 5 years ago
- Views:
Transcription
1 ICH E17 General principle n planning and design f Multi-Reginal Clinical Trials January 14th, 2017 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Pharmaceuticals fr Human Use Legal Ntice This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 2 1
2 ICH HARMONISED TRIPARTITE GUIDELINE General Principles fr Planning and Design f Multi-Reginal Clinical Trials E17 (FINAL) Nvember 16 th, 2017 ICH E17 Guideline Started in June 2014 Draft in June 2016 Finalised in Nvember Table f Cntents (E17 final) 4 2
3 1.1 Objectives f the Guideline With the increasing glbalisatin f drug develpment, it has becme imprtant that data frm multi-reginal clinical trials (MRCTs) can be accepted by regulatry authrities acrss regins and cuntries as the primary surce f evidence, t supprt marketing apprval f drugs (medicinal prducts) The purpse f this guideline is t describe general principles fr the planning and design f MRCTs with the aim f increasing the acceptability f MRCTs in glbal regulatry submissins The guideline addresses strategic prgramme issues as well as issues that are specific t the planning and design f cnfirmatry MRCTs, and it shuld be used tgether with ther ICH Guidelines, including E5, E6, E8, E9, E10, and E Scpe f the Guideline MRCT is defined in the present guideline as a clinical trial cnducted in mre than ne regin under a single prtcl. In this cntext, a regin may refer t a gegraphical regin, cuntry r regulatry regin (see Sectin 3. Glssary) The primary fcus f this guideline is n MRCTs designed t prvide data that will be submitted t multiple regulatry authrities fr drug apprval (including apprval f additinal indicatins, new frmulatins and new dsing regimens) and fr studies cnducted t satisfy pst-marketing requirements Certain aspects f this guideline may als be relevant t studies cnducted early in clinical develpment r in later phases. The present guideline mainly cvers drugs including bilgical prducts, althugh sme sectins may nt be applicable t all develpment prgrammes (e.g., pharmackinetics (PK) nt used fr preventive vaccine dse-finding). 6 3
4 2.1.1 The Value f MRCTs in Drug Develpment Basic Principles 8 4
5 1.4 Basic Principles (1) 1. Strategic use f MRCTs in drug develpment prgrammes, prperly designed and executed accrding t this guideline, can increase efficiency f drug develpment. MRCTs may enable simultaneus submissin f marketing authrisatin applicatins and supprt regulatry decisin-making in multiple regins, allwing earlier access t new drugs wrldwide. Althugh MRCTs may generally becme the preferred ptin fr investigating a new drug fr which regulatry submissin is planned in multiple regins, the ptential fr reginal differences t impact the interpretability f study results shuld be carefully cnsidered. 2. The intrinsic and extrinsic factrs imprtant t the drug develpment prgramme, shuld be identified early. The ptential impact f these factrs culd be examined in the explratry phases befre the design f cnfirmatry MRCTs. Infrmatin abut them shuld als be cllected during the cnfirmatry trial fr evaluatin f their impact n treatment effects Basic Principles (2) 3. MRCTs are planned under the assumptin that the treatment effect applies t the entire target ppulatin, particularly t the regins included in the trial. Strategic allcatin f the sample size t regins allws an evaluatin f the extent t which this assumptin hlds. 4. Pre-specified pling f regins r subppulatins, based n established knwledge abut similarities, may help prvide flexibility in sample size allcatin t regins, facilitate the assessment f cnsistency in treatment effects acrss regins, and supprt regulatry decisin-making. 5. A single primary analysis apprach fr hypthesis testing and estimatin f the verall treatment effect shuld be planned s that it will be acceptable t all cncerned regulatry authrities. A structured explratin t examine the cnsistency f treatment effects acrss regins and subppulatins shuld be planned. 10 5
6 1.4 Basic Principles (3) 6. In light f diverse reginal practices, ensuring high quality f study design and cnduct in accrdance with ICH E6 in all regins is f paramunt imprtance t ensure the study results are interpretable. Careful attentin t quality during trial planning, investigatr training, and trial mnitring will help achieve cnsistently high trial quality required fr a successful MRCT. 7. Efficient cmmunicatin amng spnsrs and regulatry authrities is encuraged at the planning stage f MRCTs, with the gal f btaining acceptance f a glbal apprach t study design acrss the different regulatry regins. 11 Majr pints described in Sectin
7 2.2.1 Pre-cnsideratin f Reginal Variability and its Ptential Impact n Efficacy and Safety At the planning stage, reginal variability, the extent t which it can be explained by intrinsic and extrinsic factrs, and its ptential t influence the study results, shuld be carefully cnsidered in determining the rle MRCTs can play in the drug develpment strategy The intrinsic and extrinsic factrs imprtant t the drug develpment prgramme, shuld be identified during the planning stage f an MRCT Pre-cnsideratin f Reginal Variability and its Ptential Impact n Efficacy and Safety Figure 2 illustrates the way in which intrinsic and/r extrinsic factrs such as disease severity (Figure 2a) r ethnicity (Figure 2b) may manifest as reginal differences in treatment respnse. 14 7
8 2.2.2 Subject Selectin In MRCTs, subject selectin shuld be carefully cnsidered t better understand and pssibly mitigate ptential surces f reginal variability and their impact n trial results Clear and specific inclusin and exclusin criteria, that are acceptable and can be applied acrss regins, shuld be included in the prtcl T harmnise subject selectin, unifrm classificatin and criteria fr diagnsis f the disease r definitin f the at-risk ppulatin shuld be implemented, such as the use f relevant guidelines fr disease definitins Selectin f Dses fr Use in Cnfirmatry MRCTs It is imprtant t execute well-planned early develpment prgrammes that include PK and/r PK-PD studies f applicable parameters, in rder t identify reginal differences which may impact dse selectin The dse regimens in cnfirmatry MRCTs (based n data frm studies mentined abve) shuld in principle be the same in all participating ethnic ppulatin If earlier trial data shw a clear difference in dse-respnse and/r expsure-respnse relatinships fr an ethnic ppulatin, it may be apprpriate t use a different dsing regimen, prvided that the regimen is expected t prduce similar therapeutic effects with an acceptable safety margin, and prvided it is scientifically justified in the study prtcl. Prspective careful planning f assessment strategies where different dses are used shuld be tailred t each case and described in the analysis plans. 16 8
9 2.2.4 Chice f Endpints The primary endpint shuld be relevant t the target ppulatin. In MRCTs, this relevance needs t be cnsidered fr all regins in the trial and with respect t the varius drug, disease and ppulatin characteristics represented in thse regins An ideal clinical trial endpint is ne that is clinically relevant, accepted in medical practice (e.g., by regulatry guidance r prfessinal sciety guidelines) and sufficiently sensitive and specific t detect the anticipated effect f the treatment The primary endpint, whether efficacy r safety, shuld satisfy these criteria as well as being acceptable t all cncerned regulatry authrities, t ensure that interpretatin f the success r failure f the MRCT is cnsistent acrss regins and amng regulatry authrities The primary endpint f MRCTs shuld be ne fr which experience is already available in the participating regins Sample Size Planning The key cnsideratin fr sample size planning, is ensuring sufficient sample size t be able t evaluate the verall treatment effect, under the assumptin that the treatment effect applies t the entire target ppulatin, particularly t the regins included in the trial Tw additinal factrs are particularly imprtant in the MRCT setting; (i) the size f the treatment effect that is cnsidered clinically relevant t all regins in the trial, and (ii) the expected variability f the primary utcme variables based n cmbining data acrss regins. 18 9
10 2.2.5 Sample Size Planning The MRCT shuld be planned t include an evaluatin f the cnsistency f treatment effects amng regins, where cnsistency is defined as a lack f clinically relevant differences If clinically relevant differences amng regins are bserved, then the MRCT prvides a unique pprtunity fr additinal learning abut the factrs that may explain these differences Reginal allcatin shuld have a scientific basis (rather than arbitrary targets), shuld supprt the evaluatin f cnsistency and shuld prvide the infrmatin needed t supprt regulatry decisins Sample Size Planning 1 Prprtinal Allcatin: Allcatin f subjects t regins in prprtin t size f regin and disease prevalence. Five examples fr sample size allcatin t regin Equal Allcatin: Allcatin f equal numbers f subjects t each regin. Preservatin f Effect: Allcatin f subjects t ne r mre regins based n preserving sme specified prprtin f the verall treatment effect. Lcal Significance: Allcatin f a sufficient number f subjects t be able t achieve significant results within each regin. A balance between #1 and #2 is recmmended t ensure that recruitment is feasible and able t be cmpleted in a timely fashin, but als t prvide sufficient infrmatin t evaluate the drug in its reginal cntext. 5 Fixed Minimum Number: Allcatin f a fixed minimum number f subjects t a regin
11 2.2.5 Sample Size Planning Pled regins: Pled Regins and Subppulatins Pling sme gegraphical regins, cuntries r regulatry regins at the planning stage, if subjects in thse regins are thught t be similar enugh with respect t intrinsic and/r extrinsic factrs relevant t the disease and/r drug under study. Pled subppulatins: Pling a subset f the subjects frm a particular regin with similarly defined subsets frm ther regins whse members share ne r mre intrinsic r extrinsic factrs imprtant fr the drug develpment prgramme at the planning stage. Pled subppulatins is assumed as ethnicity-related subgrup particular imprtant in the MRCT setting Sample Size Planning Pled Regins and Subppulatins Pre-specified pling f regins r subppulatins may help prvide flexibility in sample size allcatin t regins, facilitate the assessment f cnsistency in treatment effects acrss regins, and supprt regulatry decisin-making. The pling strategy shuld be justified based n the distributin f the intrinsic and extrinsic factrs knwn t affect the treatment respnse, and the disease under investigatin and similarity f thse factrs acrss regins. Fr example, pling Canada and the United States int a Nrth American regin is ften justified because f similar medical practices and similar use f cncmitant medicatins. Pling strategies shuld be specified in the study prtcl and statistical analysis plan, if applicable
12 2.2.6 Cllecting and Handling f Efficacy and Safety Infrmatin Adherence t GCP is critical fr any clinical trial t meet its stated bjectives and is particularly imprtant in an MRCT, because f the crdinatin required t cnduct a trial in diverse gegraphic regins. Methds f cllecting and handling efficacy and safety infrmatin shuld be standardised acrss participating regins. It is als imprtant t prvide standardised training fr investigatrs and study persnnel in each regin befre initiating the trial in that regin t ensure that the trial bjectives are met thrugh standardised implementatin f the study prtcl Statistical Analysis Planning The analysis strategy shuld be planned t enable the qualitative and/r quantitative evaluatin f benefit/risk acrss regins r imprtant subppulatins represented in the MRCT. In planning an MRCT, the primary analysis strategy shuld carefully cnsider (1) the target ppulatin, (2) the endpints/variables f primary interest (3) the relevant intrinsic and extrinsic factrs in the multi-reginal, multi-subppulatin cntext (4) the ppulatin-level summary f data required t describe the treatment effect. Fr mst MRCTs, the primary analysis will crrespnd t a test f the hypthesis abut the treatment effect and the estimatin f that effect, cnsidering data frm all regins and subppulatins included in the trial
13 Statistical Analysis Planning The statistical analysis strategy shuld include the evaluatin f the cnsistency f treatment effects acrss regins and subppulatins Graphical displays Mdel-based estimatin Descriptive summaries MRCT data Test f treatment by regin interactin Internal cnsistency within the MRCT (amng endpints) Cnsistency with external data (the ther trial results) The evaluatin f reginal cnsistency is nt cnsidered a cnfirmatry exercise but rather a gateway fr further explratin Statistical Analysis Planning In case f clinically relevant differences in treatment effects amng regins, a structured explratin f these differences shuld be planned. Factrs knwn a priri t vary amng regins (e.g., disease severity, race, ther subject characteristics) and hypthesized t be prgnstic r predictive shuld be planned fr and evaluated in the analysis mdel Unexpected reginal differences may be bserved, and pst-hc analyses shuld be used fr further investigatin. Factrs knwn t be prgnstic fr the disease wuld be examined first Reginal differences may require further pst-hc investigatin t either identify plausible reasns fr the differences r t better understand the bserved hetergeneity. In sme cases, additinal data, including data frm ther clinical trials, r supprtive evidence frm ther surces, may be needed t understand the reginal differences bserved These eventualities shuld be carefully cnsidered at the planning stage
14 Selectin f Cmparatrs The chice f cntrl grups shuld be cnsidered in the cntext f the available standard therapies, the adequacy f the evidence t supprt the chsen design, and ethical cnsideratins. Cmparatrs in MRCTs shuld in principle be the same in all participating regins. The justificatin (including safety cnsideratins) fr the use f an unapprved drug shuld therefre be described in the prtcl based n scientific infrmatin, treatment guidelines and ther relevant dcuments Handling Cncmitant Medicatins In general, drugs used cncmitantly with the investigatinal drug shuld be the same thrughut the regins t the extent pssible, but there may be sme differences in the drugs and/r dses actually used due t variatins in medical practices. This culd be acceptable if nt expected t substantially impact trial results. In circumstances where apprved drugs are cmbined with an investigatinal drug, the same dsage regimen in all regins shuld generally be applied. If required by prtcl, cncmitant medicatins that are nt apprved in a regin shuld have their use justified based n scientific infrmatin, treatment guidelines and ther relevant dcuments
15 Impacts f E17 guideline Earlier access t innvative therapies Synchrnize clinical drug develpment acrss different regins Avid duplicatin Reduce the need fr regin specific studies and bridging studies Prmte internatinal harmnizatin A glbally harmnized apprach t drug develpment shuld be cnsidered first Prvide better evidences fr drug apprval in each regin Incrprate latest knwledge and experience frm regins int ne trial Develp an infrastructure fr glbal drug develpment Cnducting high quality MRCTs is a valuable investment in mdern drug develpment 29 Thank Yu! Internatinal Cnference n Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 15
Kootenai River Restoration Master Plan: Master Plan Overview
Ktenai River Restratin Master Plan: Master Plan Overview Ktenai River Restratin Prject #200200200 Restre Natural Recruitment Ktenai River White Sturgen Prject Overview In late 2006, the KTOI received prject
More informationPoints to consider: Does the degree of discrepancy in the data require an intervention? If yes: o o o o
ISMPP Cde f Ethics cases Preamble The current ethics cases were reviewed fr relevance and areas fr imprvement were identified. In additin, the cases were aligned with the new Cde f Ethics (Nvember 1, 2016).
More informationEMD Serono Position Statement on Responsible Clinical Trial Data Sharing For External Use
EMD Sern Psitin Statement n Respnsible Clinical Trial Data Sharing Fr External Use Why it Matters EMD Sern believes that as a bipharmaceutical cmpany, the sharing f infrmatin related t cmpany spnsred Clinical
More information0XXX: Meter Reading Submission for Advanced & Smart Metering. Stage 01: Request
Stage 01: Request 0XXX: Meter Reading Submissin fr Advanced & Smart Metering At what stage is this dcument in the prcess? The rllut f Advanced and Smart Metering delivers the pprtunity t utilise mre frequent
More informationIndependent scientific review of claims by qualified bodies;
Directr: Fd Cntrl Directr-General f Health Private Bag X828 Pretria 0001 Submissin f cmments n: Regulatins Relating t the Labelling and Advertising f Fds: Amendment N. R 429. Gazette N. 37695 Published
More informationCorporate Value Chain (Scope 3) Accounting & Reporting Standard. Summary of Changes
Nvember 2010 Wrld Business Cuncil fr Sustainable Develpment Crprate Value Chain (Scpe 3) Accunting & Reprting Standard Summary f Changes 1. Intrductin This dcument summarizes the changes made t the GHG
More informationREQUEST FOR PROPOSALS FY-2018 RESEARCH ON GLOBAL APPROACHES TO LAND VALUE CAPTURE
REQUEST FOR PROPOSALS FY-2018 RESEARCH ON GLOBAL APPROACHES TO LAND VALUE CAPTURE RESEARCH THEME The Lincln Institute f Land Plicy ( Lincln Institute ) invites prpsals fr riginal research papers and case
More informationGuidance notes for completing the International Start-up Form
Guidance ntes fr cmpleting the Internatinal Start-up Frm These guidance ntes are designed t supprt yu in cmpleting the Internatinal start-up frm. Yu will als need t refer t a) yur Stage 2 applicatin frm
More informationAlumni and Supporters Privacy Notice
Alumni and Supprters Privacy Ntice Hw we use yur persnal data (fr alumni and supprters) The University regards the alumni service as an imprtant and integral part f the University's lng term cmmitment
More informationIESBA Meeting (March 2013) Agenda Item
Agenda Item 7-A Backgrund Lng Assciatin f Senir Persnnel (Including Partner Rtatin) with an Audit Client Matters fr Cnsideratin 1. Paragraph 290.150 f the IESBA Cde f Ethics fr Prfessinal Accuntants (the
More informationKNOWLEDGE CAPTURE INTERVIEW
Inter-American Develpment Bank KNOWLEDGE AND LEARNING SECTOR (KNL) TECHNICAL NOTES KNOWLEDGE CAPTURE INTERVIEW N. IDB-TN-424 June 2012 KNOWLEDGE CAPTURE INTERVIEW Inter-American Develpment Bank 2012 http://www.iadb.rg
More informationCharter (draft v0.2) (1)(a) Name. (1)(a) Prepared By. (1)(b) Purpose. (1)(b) Business Problem. Evolution of Product Information
Charter (draft v0.2) Subject: OASIS DITA Pharmaceutical Cntent Subcmmittee DRAFT Charter Date: 21-April-2009 Versin: 0.2 (1)(a) Name Full Name: OASIS DITA Pharmaceutical Cntent Subcmmittee Shrt Name: DITA-PC-SC
More informationIMI2 PROPOSAL TEMPLATE FIRST STAGE PROPOSAL
IMI2 PROPOSAL TEMPLATE FIRST STAGE PROPOSAL IN TWO-STAGE PROCEDURE (TECHNICAL ANNEX) RESEARCH AND INNOVATION ACTIONS & INNOVATION ACTIONS Nte: This is fr infrmatin nly. The definitive template fr yur call
More informationCommunications White Paper
Intrductin The quality and effectiveness f the cmmunicatin between the prject and the stakehlder grups is a significant cntributing factr t prject success r failure. Cmmunicatin is abut sending and receiving
More informationThe role of non-animal safety assessment methods in implementation of the new TSCA
The rle f nn-animal safety assessment methds in implementatin f the new TSCA Catherine Willett Humane Sciety f the United States Humane Sciety Internatinal The Frank R. Lautenberg Chemical Safety fr the
More informationBIOMARKERS RELATED TO DRUG OR BIOTECHNOLOGY PRODUCT DEVELOPMENT: CONTEXT, STRUCTURE AND FORMAT OF QUALIFICATION SUBMISSIONS E16
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE BIOMARKERS RELATED TO DRUG OR BIOTECHNOLOGY PRODUCT
More informationRecords Management Policy
Recrds Management Plicy Main Authr: Cnsultatin Rute: Apprved By: Date f Issue: Applicable: Organisatinal wide Versin: 1.0 Review Date: February 2011 Versin 1.0: February 2010 Change Cntrl Versin Change
More informationICH Q12 and reduction in post approval complexity Dr Frank Montgomery, Global Head, Reg CMC, AstraZeneca UK EFPIA Expert to ICH Q12 EWG
ICH Q12 and reductin in pst apprval cmplexity Dr Frank Mntgmery, Glbal Head, Reg CMC, AstraZeneca UK EFPIA Expert t ICH Q12 EWG Tpra 2017 Oct 2017 Disclaimer The views presented d nt necessarily reflect
More informationProject document. HWTS Promotion in schools
Prject dcument HWTS Prmtin in schls Octber 2011 1 Prject title HWTS and Hygiene Prmtin in schls 2 Prject Backgrund The prject bjectives are t develp a target-grup riented training manual and t reach 9
More informationPay policy programme for Lund University
Dnr I F 9 5307/1999 1 Pay plicy prgramme fr Lund University apprved by the University Bard n 7 April 2000 The basic aim f the pay plicy is t help the University in achieving its targets. Mtivated, cmmitted
More informationOSPAR Regional Action Plan for Prevention and Management of Marine Litter in the North-East Atlantic
OSPAR Cnventin fr the Prtectin f the Marine Envirnment f the Nrth-East Atlantic OSPAR Reginal Actin Plan fr Preventin and Management f Marine Litter in the Nrth-East Atlantic Summary: OSPAR Ministers had
More informationGuidelines on Use of Electronic Data Collection in Censuses: Systems for Management and Monitoring Field Operations
Guidelines n Use f Electrnic Data Cllectin in Censuses: Systems fr Management and Mnitring Field Operatins Management and Mnitring Systems Increasing access t mdern technlgy has led t significant prgress
More informationHOUSING NEED AND DEMAND STUDY
HOUSING NEED AND DEMAND STUDY (Dcument Template) March 2010 Intrductin: BC Husing cnsiders the needs f all municipalities in the Prvince during deliberatins n the lcatin f new affrdable husing prjects.
More informationOrganizational Support Policy Approved by the AGU Board of Directors in April 2015
Organizatinal Supprt Plicy Apprved by the AGU Bard f Directrs in April 2015 I. Preamble AGU members cmprise the largest single rganizatin dedicated t the advancement f Earth and space science. Uniting
More informationMethod 1: Establish a rating scale for each criterion. Some options are:
Decisin Matrix Als called: Pugh matrix, decisin grid, selectin matrix r grid, prblem matrix, prblem selectin matrix, pprtunity analysis, slutin matrix, criteria rating frm, criteria-based matrix. Descriptin
More informationCall for Papers SYSTEMS DO FOR YOU? Portland, OR June 13 15, Submit abstracts to:
Call fr Papers TES 2017 THE 2017 4 TH INTERNATIONAL TRANSACTIVE ENERGY SYSTEMS CONFERENCE AND WORKSHOP MAXIMIZING YOUR VALUE: WHAT CAN TRANSACTIVE ENERGY SYSTEMS DO FOR YOU? Prtland, OR June 13 15, 2017
More informationITIL FOUNDATION SUMMARY NOTES. Sessions
ITIL FOUNDATION SUMMARY NOTES Sessins 2 Service Management as a Practice 2 3 Service Lifecycle 3 4 Service Strategy 4 5 Service Design 5 6 Service Transitin 6 7 Service Operatin 7 8 Cntinual Service Imprvement
More informationOutbreak, Surveillance and Investigation Reports (OSIR)
Outbreak, Surveillance and Investigatin Reprts (OSIR) is an nline publicatin n epidemilgical wrks f health prfessinals in Asia and the Pacific. Backgrund Few jurnals regularly publish utbreak investigatins
More informationBest Practices for Safety Action Review Boards
Best Practices fr Safety Actin Review Bards By Brian Hughes, Vice President f Slgic A versin f this article appeared in the May 2011 issue f Prfessinal Safety magazine. Many safety departments I wrk with
More informationUNC 0594R: Meter Reading Submission for Advanced & Smart Metering. UNC Request Workgroup Report
UNC Request Wrkgrup Reprt At what stage is this dcument in the prcess? UNC 0594R: Meter Reading Submissin fr Advanced & Smart Metering The rllut f Advanced and Smart Metering delivers the pprtunity t utilise
More informationA. Rational for change
Applicatin made by the Slicitrs Regulatin Authrity Bard t the Legal Services Bard under Part 3 f Schedule 4 t the Legal Services Act 2007, fr the apprval f changes t regulatry arrangements relating t the
More informationRequest for Proposal
Request fr Prpsal DMDII-17-02 Advanced Analytics fr Supply Chain Operatins Technlgy Thrust Area: Agile, Resilient Supply Chain Revisin 1.0 Release Date: 4 August 2017 POC: Sctt Kruse Prject Innvatin Engineer
More informationGiovanni Migliaccio Head, Section of Gene and Cell Therapy Istituto Superiore di Sanità
REGULATION (EC) N 1394/2007 Advanced Therapy Medicinal Prducts Givanni Migliacci Head, Sectin f Gene and Cell Therapy Istitut Superire di Sanità Rme Italy REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE
More informationWorking Families Success Network in Community Colleges Definitions and Expected Design Elements
Wrking Families Success Netwrk in Cmmunity Clleges Definitins and Expected Design Elements Cre Prgram and Service Delivery Elements Clleges shuld prvide services in each f the three WFSNCC cre pillars:
More informationNotes and guidance: Paper 1 Section B Poetic voices
Ntes and guidance: Paper 1 Sectin B Petic vices This resurce explains hw the questin in the specimen assessment materials fr AS Paper 1, Sectin B, Petic vices, addresses the assessment bjectives, with
More informationInquiry processing. 1. Purpose. 2. Scope. 3. Description
1. Purpse T describe the assessment f inquiry dssiers submitted t ECHA accrding t Article 26(1) f the REACH Regulatin and the steps taken t ensure that the data sharing amng ptential and previus registrants
More informationMonitoring and. Prof. Jay Aronson
Mnitring and Evaluatin Prf. Jay Arnsn Mnitring Mnitring Gal: assess prgress f prject/prgram at regular intervals; find ut what s ging n (budget, persnnel, deadlines, prgress, areas needing mre wrk, etc.)
More informationOperator Certification Program Proposed Draft ORO/OIC Guideline. Wastewater Practitioners Group Meeting November 29, 2017
Operatr Certificatin Prgram Prpsed Draft ORO/OIC Guideline Wastewater Practitiners Grup Meeting Nvember 29, 2017 Tday s Tpic Overall Respnsible Operatr (ORO) and Operatr-in-Charge (OIC) Updating the Guideline
More informationAppendix C: Country Case Study Methodology
Appendix C: Cuntry Case Study Methdlgy Guiding Principles Cuntry cases fllw a multiple cuntry case study design, that is, fcus n three reginal clusters each with three sets f PPP prjects with distinct
More informationHR66 Research Passports Policy
Research Passprts Plicy Plicy: HR66 Plicy Descriptr The NHS wrking with Higher Educatin Institutins (HEIs) has a Research Passprt system. It cnsists f a series f pre-engagement checks fr University staff/students
More informationIBM Global Services. Server Optimization ... Trends and Value Proposition That Can Drive Efficiencies and Help Businesses Gain A Competitive Edge
IBM Glbal Services Server Optimizatin.......... Trends and Value Prpsitin That Can Drive Efficiencies and Help Businesses Gain A Cmpetitive Edge Intrductin A typical rganizatin s success and ability t
More informationAnnex D: The development of access and participation targets
Annex D: The develpment f access and participatin targets Backgrund 1. English higher educatin prviders have made steady prgress t imprve access and participatin ver the past decade, but there is still
More informationCall for Expression of Interest
Call fr Expressin f Interest Pst Title: Expert Duty Statin: Hme-based Reference: UNWTO/HHRR/CFE/15/RDAP/2018 Start Date: As sn as pssible Department: Reginal Department fr Asia and the Pacific Duratin:
More informationPrinciple and Procedure of Analytical Test Method Validation for GMP Regulated Industry
Principle and Prcedure f Analytical Test Methd Validatin fr GMP Regulated Industry Regulatry Basis: FDA Quality Systems Regulatins Reference: FDA CFR - Cde f Federal Regulatins Title 21 Purpse The purpse
More informationDirectives 90/385/EEC and 93/42/EEC MEDICAL DEVICES. Clinical Evaluation Report Presentation guide
Directives 90/385/EEC and 93/42/EEC MEDICAL DEVICES Clinical Evaluatin Reprt Presentatin guide The elements f the clinical evaluatin reprt are recrds f the prcess that the manufacturer applies t the identificatin,
More informationMEDICINES CONTROL COUNCIL
Oversight and Mnitring in Clinical Trials MEDICINES CONTROL COUNCIL OVERSIGHT AND MONITORING IN CLINICAL TRIALS This guideline assists spnsrs f clinical investigatins in develping mnitring strategies and
More informationNomination for Merit Award or Contribution Points
Nminatin fr Merit Award r Cntributin Pints Wh is this dcument fr? Line Managers can submit individuals and/r teams fr cnsideratin fr a merit award r cntributin pints using ne f the frms included here.
More informationLearning from Recent Modeling Projects. Shanon Phillips- OCC Steve Patterson- BioXDesign
Learning frm Recent Mdeling Prjects Shann Phillips- OCC Steve Pattersn- BiXDesign OCLWA April 5-6, 2017 Are we Insane? Hw many majr watersheds/waterbdies in OK have been mdeled just ONE time? When an
More informationManaging Immigration Risk
Managing Immigratin Risk Strategies fr educatin prviders [Type text] Streamlined visa prcessing arrangements strategies fr cnsideratin by educatin prviders 1 Page 1 Table f Cntents Simplified Student Visa
More informationOperating Year(s):
2011 2012 Operatinal Plan Prject Prpsals Ecsystem Carbn Surces and Strage: Infrmatin t Quantify and Manage fr Greenhuse Gas Emissins Reductins Planned Budget: 2011: C$250,000 2012: C$320,000 Operating
More informationCDM Plan Submission and Review Criteria Rules
Cnservatin First Framewrk LDC Tl Kit Final v4.0 January 17, 2018 CDM Plan Submissin and Review Rules 1) Purpse and definitins 1.1 These Rules set ut: a) the rles, respnsibilities and timing fr CDM Plan
More informationHEALTHY START RAPID EVALUATION OF EARLY IMPACT ON BENEFICIARIES, HEALTH PROFESSIONALS, RETAILERS AND CONTRACTORS
Tavistck Institute HEALTHY START RAPID EVALUATION OF EARLY IMPACT ON BENEFICIARIES, HEALTH PROFESSIONALS, RETAILERS AND CONTRACTORS EXECUTIVE SUMMARY This reprt presents the findings frm the rapid evaluatin
More informationHEALTH AND SAFETY POLICY MISSION STATEMENT
HEALTH AND SAFETY POLICY MISSION STATEMENT IPLOCA is ttally cmmitted t the prmtin f health and safety in all areas f its influence and subscribes t the philsphy that all accidents are preventable. Therefre
More informationHEALTH AND SAFETY POLICY MISSION STATEMENT
HEALTH AND SAFETY POLICY MISSION STATEMENT IPLOCA is ttally cmmitted t the prmtin f health and safety in all areas f its influence and subscribes t the philsphy that all accidents are preventable. Therefre
More informationCopies: Lisa Kellogg Janis Lutrick Mala Pattanayek Wini Curley Adrienne LaPierre Kim Walsh
MEMO T: Yvnne Meeks/PG&E Cpies: Lisa Kellgg Janis Lutrick Mala Pattanayek Wini Curley Adrienne LaPierre Kim Walsh ARCADIS U.S., Inc. 100 Mntgmery Street Suite 300 San Francisc Califrnia 94104 Tel 415 374
More informationEmpowered Workgroups. A process area at Level 4: Predictable
Empwered Wrkgrups A prcess area at Level 4: Predictable Purpse Descriptin The purpse f Empwered Wrkgrups is t invest wrkgrups with the respnsibility and authrity fr determining hw t cnduct their business
More informationDown Under. Project Management Essential in Process Management Projects
A BPTrends Clumn Dwn Under December 2007 Jhn Jestn & Jhan Nelis BPM Cnsultants, Sydney Australia Authrs: Business Prcess Management Practical Guidelines t Successful Implementatins jhn.jestn@managementbyprcess.cm
More informationReregistration of voluntarily deregistered CDM project activities
Paragraph 4 f the anntated agenda, Annex 1 Reregistratin f vluntarily deregistered CDM prject activities CDM EB 87 Paris, France, 23 27 Nvember 2015 UNFCCC Secretariat SDM prgramme Prcedural backgrund
More informationLINKING THE ACCOUNTING FRAMEWORKS OF THE SEEA AND THE TSA
UNWTO Statistics and Turism Satellite Accunt Prgramme COMMITTEE ON STATISTICS AND THE TOURISM SATELLITE ACCOUNT Seventeenth meeting UNWTO Headquarters, Madrid, Spain 24-25 January 2017 LINKING THE ACCOUNTING
More informationSt Albans Musical Theatre Company
St Albans Musical Theatre Cmpany ST ALBANS MUSICAL THEATRE COMPANY PRIVACY POLICY This ntice describes hw St Albans Musical Theatre Cmpany (als referred t as "SAMTC", "we", "us" r ur ), prcess yur persnal
More informationGUIDE TO TREND MAPPING
GUIDE TO TREND MAPPING Example Trend Map 1 TREND MAPPING OVERVIEW What is a trend map? A trend map is a visual depictin f relevant trends influencing the system arund a given tpic. It is develped using
More informationVI. ALTERNATIVES TO THE MASTER PLAN A. INTRODUCTION
VI. ALTERNATIVES TO THE MASTER PLAN A. INTRODUCTION INTRODUCTION As stipulated in Sectin 21002.1(a) f the CEQA Statutes (Public Resurces Cde): The purpse f an envirnmental impact reprt is t identify the
More informationTHIRD SECTOR FIRST Working together to put the third sector first
THIRD SECTOR FIRST Wrking tgether t put the third sectr first Jb title: Emplyer: Reprting t: Develpment Officer (Lead Officer fr Scial Enterprise) Third Sectr First, Dumfries & Gallway Operatins Manager
More informationMonitoring, Evaluation and Adaptive Management Following INFFER Assessment (INFFER step 7)
Mnitring, Evaluatin and Adaptive Management Fllwing INFFER Assessment (INFFER step 7) www.inffer.rg David Pannell, Geff Park, April Curatl, Anna Rberts, Stephanie Spry, Sally Marsh Intrductin The Investment
More informationAcceptance criteria for process capability indexes generated from statistical tolerance intervals as per ISO
Acceptance criteria fr prcess capability indexes generated frm statistical tlerance intervals as per Backgrund Justificatin fr sampling plans and statistical analysis f results is a requirement fr prcess
More informationThis handout relates to the Writing your Report webinar and covers the following: Advice on what to do after you have completed your report
The Ryal Sciety fr the Preventin f Accidents Writing yur Reprt Rad Safety Evaluatin Webinar Handut: Writing yur Reprt Evaluatin webinar handut Intrductin This handut relates t the Writing yur Reprt webinar
More informationGuidance on the Privacy and Electronic Communications (EC Directive) Regulations
Infrmatin Security Guidance Title: Status: Guidance n the Privacy and Electrnic Cmmunicatins (EC Directive) Regulatins Released 1. Purpse This guidance n the Privacy and Electrnic Cmmunicatins (EC Directive)
More informationWABC Guidelines. For Researchers Investigating Business-Coaching- Related Topics
WABC Guidelines Fr Researchers Investigating Business-Caching- Related Tpics WABC GUIDELINES: Fr Researchers Investigating Business-Caching-Related Tpics (2016-SEP) 1 Cntents 3 Preamble 3 Intended Audience
More informationTeam Assignment 5: Locating & Evaluating Magazine and Newspaper Articles
Team Assignment 5: Lcating & Evaluating Magazine and Newspaper Articles Team Assignment 5: Lcating & Evaluating Magazine and Newspaper Articles This assignment will intrduce yu t the fundamentals f lcating
More informationMeeting Agenda Project Management and Oversight Subcommittee (PMOS)
Meeting Agenda Prject Management and Oversight Subcmmittee (PMOS) March 6, 2013 1:00 p.m. 5:00 p.m. Muntain Hyatt Regency Albuquerque Fiesta 3-4 Rm 330 Tijeras Avenue NW Albuquerque, NM 87102 Intrductins
More informationThe BLOOM Performance Review Decision Guide
The BLOOM Perfrmance Review Decisin Guide Intrductin Planning yur perfrmance review prcess needs careful cnsideratin. Sme questins yu might be cnsidering are: 1. Hw ften will the rganizatin cmplete frmal
More informationAnnual Plan
Accunting Standards Bard Annual Plan 2017-2018 Table f Cntents Abut the Accunting Standards Bard 2 Overview 2 2017-2018 AcSB bjectives, activities and perfrmance indicatrs 3 Publicly accuntable enterprises
More informationThe Role of the CRC in a Clinical Trial
The Rle f the CRC in a Clinical Trial Dr Saurendra Das Cuntry Head & Directr f Operatins, Excel Life Sciences The team cnducting a clinical trial at a site cnsists f the principal investigatr (PI), the
More informationUnited Nations Statistics Division Programme in Support of the 2020 Round of Population and Housing Censuses
1 United Natins Statistics Divisin Prgramme in Supprt f the 2020 Rund f Ppulatin and Husing Censuses Sessin 8 Main Drivers and Decisin-Making n the Use f Electrnic Data Cllectin Technlgies Srdjan Mrkić
More informationCompleting the Case Report Form
Cmpleting the Case Reprt Frm Clinical S.O.P. N.: 14 Cmpiled by: Apprved by: Review date: Nvember 2016 DOCUMENT HISTORY Versin number Detail f purpse / change Authr / edited by 1.0 New SOP Shna Brearley
More informationWave Management Consulting
Wave Management Cnsulting Wave Management Cnsulting Crprate Prfile Wave Management Cnsulting www.wmc-me.cm inf@wmc-me.cm Jrdan +962795780560 P. O. Bx 963550 Jrdan Wave Management Cnsulting Crprate Prfile
More information2018 SQF INTERNATIONAL CONFERENCE Presentation Proposal Guidelines
2018 SQF INTERNATIONAL CONFERENCE Presentatin Prpsal Guidelines We are accepting yur presentatin ideas t share insights, best practices, emerging trends, grundbreaking research and critical industry updates
More informationUS Prescribing Information & Safety Labeling April 22 April 23, 2013 PERI Training Facility ~ Arlington, Virginia
Tentative Agenda US Prescribing Infrmatin & Safety Labeling April 22 April 23, 2013 PERI Training Facility ~ Arlingtn, Virginia Mnday, April 22, 2013 Tab N. 7:30 8:00 AM Registratin and Cntinental Breakfast
More informationGuidelines on Use of Electronic Data Collection in Censuses: Systems for Management and Monitoring Field Operations
Guidelines n Use f Electrnic Data Cllectin in Censuses: Systems fr Management and Mnitring Field Operatins Management and Mnitring Systems Establish a centralized system fr an effective management, mnitring
More informationFrequently Asked Questions for UNDAF Evaluations
Guidance Dcument Frequently Asked Questins fr UNDAF Evaluatins Prepared in cllabratin with UNDOCO, these Frequently Asked Questins prvide answers t questins regarding varius aspects related t UNDAF evaluatin.
More informationDigital Advisory Services Professional Service Description Software Defined Networking Strategy and Roadmap
Digital Advisry Services Prfessinal Service Descriptin Sftware Defined Netwrking Strategy and Radmap 1. Descriptin f Services. 1.1 Sftware Defined Netwrking Strategy and Radmap. Verizn will prvide Sftware
More informationCareer Entry and Development Profile Companion Guide. A Guide for ITT Tutors and Induction Tutors
Career Entry and Develpment Prfile Cmpanin Guide A Guide fr ITT Tutrs and Inductin Tutrs Intrductin Wh is the cmpanin guide fr? This guide is fr initial teacher training (ITT) tutrs wrking with trainees/teachers,
More informationGuidelines on Use of Electronic Data Collection in Censuses: Decision-making in the Adoption of Electronic Data Collection
1 Guidelines n Use f Electrnic Data Cllectin in Censuses: Decisin-making in the Adptin f Electrnic Data Cllectin United Natins Statistics Divisin Decisin making prcess Steps fr making a decisin 1. Develping
More informationINTRODUCTION. If additional information is needed, please contact The IIA Research Foundation:
INTRODUCTION The Institute f Internal Auditrs Research Fundatin TM (IIARF TM ) is the glbal leader in prviding research and knwledge resurces t enhance the internal audit prfessin. The IIARF cntinually
More informationOpen Access Policy for Research and Scholarly Outputs
University f Cumbria Open Access Plicy fr Research and Schlarly Outputs Octber 2017 NB. This plicy is available n the University f Cumbria website and it shuld be nted that any printed cpies are uncntrlled
More informationQuestions and Answers
Questins and Answers Fr: Instructr Led and Online Training Supprt Blanket Purchase Agreement Issued by: Insight Systems Crpratin (hereinafter PRIME r Insight) In supprt f: The Feed the Future Knwledge-Driven
More informationSector Strategy and Action Plan Development
Request fr Prpsal Sectr Strategy and Actin Plan Develpment Reference Number: 1501-01 Issued: January 27, 2015 Respnses Due: February 20, 2015 Calgary Ecnmic Develpment Ltd 731 1 st Street SE Calgary, AB
More informationBIRMINGHAM CITY COUNCIL STRATEGY FOR OPEN DATA
What we are trying t achieve BIRMINGHAM CITY COUNCIL STRATEGY FOR OPEN DATA This strategy sets ut hw Birmingham City Cuncil will prvide regular cmprehensive releases f public pen data and hw it will use
More informationPilot programme on a Clinical Compound Bank for Repurposing
Pilt prgramme n a Clinical Cmpund Bank fr Repurpsing Tpic: Cardivascular diseases and diabetes Tpic: Respiratry diseases Tpic: Neurdegenerative diseases Tpic: Rare/rphan diseases All infrmatin regarding
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL JOINT RESEARCH CENTRE Directorate B Growth and Innovation Circular Economy and Industrial Leadership
EUROPEAN COMMISSION DIRECTORATE-GENERAL JOINT RESEARCH CENTRE Directrate B Grwth and Innvatin Circular Ecnmy and Industrial Leadership Seville, 6 th April 2018 Level(s) testing phase Guidance and rules
More informationSAMPLE PROPOSAL. You are invited to submit a presentation proposal that addresses the Symposium theme:
SAMPLE PROPOSAL Yu are invited t submit a presentatin prpsal that addresses the Sympsium theme: "Sharing applicatins, success stries and lessns learned in reliability, durability and maintainability engineering."
More informationSTRATEGY THEME BASIN VP Laurie Tollefson and VP Dr. Mohamed Wahba
Minutes f the 66 th IEC Meeting Annex 5 [IEC Item 7, Para 18] General STRATEGY THEME BASIN VP Laurie Tllefsn and VP Dr. Mhamed Wahba The technical activities f ICID are rganized under fur strategy themes:
More informationGuidelines on Use of Electronic Data Collection in Censuses: Multi-Mode Data Collection Approach
Guidelines n Use f Electrnic Data Cllectin in Censuses: Multi-Mde Data Cllectin Apprach Multi-mde data cllectin Objectives f the use f multi-mde apprach: t imprve cverage, in a cst effective manner - Especially
More informationNEW FERTILIZER REGULATION
www.fertilizerseurpe.cm www.prductstewardship.eu www.danfertilizers.cm NEW FERTILIZER REGULATION POSITION OF FERTILIZERS EUROPE ON PRESENTATION AND COMMENTS MADE BY DG ENTERPRISE ON ESSENTIAL SAFETY AND
More informationAN OVERVIEW OF THE REGULATION OF BIOLOTECHNOLOGICAL AND BIOSIMILAR PRODUCTS IN PERÚ
AN OVERVIEW OF THE REGULATION OF BIOLOTECHNOLOGICAL AND BIOSIMILAR PRODUCTS IN PERÚ Susan Katherin Zavala Clma Area f Bilgical Prducts- UFPBNDYO Directrate f Pharmaceutical Prducts General Directrate f
More informationMarketing Research: Process and Systems for Decision Making
Chapter 2 Marketing Research: Prcess and Systems fr Decisin Making High-Level Chapter Outline I. The Rle f Marketing Research II. The Marketing Research Prcess A. Purpse f the Research B. Plan f the Research
More informationCompetitive Neutrality in the Presence of State Owned Enterprises
Cmpetitive Neutrality in the Presence f State Owned Enterprises BIAC Submissin t the OECD Crprate Gvernance Cmmittee 16 Nvember 2010 1. BIAC is pleased that the OECD is undertaking a wrk prgramme n the
More information9707 BUSINESS STUDIES
CAMBRIDGE INTERNATIONAL EXAMINATIONS GCE Advanced MARK SCHEME fr the May/June 2014 series 9707 BUSINESS STUDIES 9707/31 Paper 3 (Case Study), maximum raw mark 100 This mark scheme is published as an aid
More informationYale University Institutional Review Boards
Yale University Institutinal Review Bards IRB Plicy 630 Requirements fr the Applicatin f Gd Clinical Practice (GCP) t the Cnduct f Clinical Trials Respnsible Office Office f Research Administratin Effective
More informationRequest for Quotes PennDOT Leadership Academy for Managers (PLAM) Solicitation Number:
www.dt.state.pa.us Request fr Qutes PennDOT Leadership Academy fr Managers (PLAM) Slicitatin Number: 6100041372 Curse Title: Curse Date(s) & Lcatins: PennDOT Leadership Academy fr Managers (PLAM) This
More information